“Ever increasing patient demand, rationalisation of manufacturing pharma network, combined with the opening of multiple new markets and tightening regulatory and quality frameworks, mean that the pressures on pharmaceutical manufacturing are greater than ever before, “ says Hans-Joerg Brinkmann, Legacy’s site director. “In response to this we are delighted to have made these additions to our management team which will enable Legacy to further expand our already strong international client base, especially in Asia. We have both the experience of working in established and emerging markets and the flexibility to seamlessly ramp up production as demand accelerates.”